Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Beam Therapeutics (BEAM) EBT Margin (2019 - 2025)

Historic EBT Margin for Beam Therapeutics (BEAM) over the last 7 years, with Q3 2025 value amounting to 1162.38%.

  • Beam Therapeutics' EBT Margin fell 4849200.0% to 1162.38% in Q3 2025 from the same period last year, while for Sep 2025 it was 744.68%, marking a year-over-year decrease of 7058400.0%. This contributed to the annual value of 593.06% for FY2024, which is 5583400.0% down from last year.
  • Latest data reveals that Beam Therapeutics reported EBT Margin of 1162.38% as of Q3 2025, which was down 4849200.0% from 1208.26% recorded in Q2 2025.
  • Beam Therapeutics' EBT Margin's 5-year high stood at 45.59% during Q4 2023, with a 5-year trough of 3339900.0% in Q1 2021.
  • Its 5-year average for EBT Margin is 228299.07%, with a median of 677.47% in 2024.
  • Its EBT Margin has fluctuated over the past 5 years, first plummeted by 2000000000bps in 2021, then skyrocketed by 2000000000bps in 2022.
  • Over the past 5 years, Beam Therapeutics' EBT Margin (Quarter) stood at 126.71% in 2021, then crashed by -47bps to 186.4% in 2022, then soared by 124bps to 45.59% in 2023, then tumbled by -759bps to 300.51% in 2024, then tumbled by -287bps to 1162.38% in 2025.
  • Its last three reported values are 1162.38% in Q3 2025, 1208.26% for Q2 2025, and 1464.82% during Q1 2025.